{"url_path":"/sec/txmd/8-k/2026-08-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-087756-index.html","accession_number":"0001213900-26-087756","cik":"0000025743","ticker":"TXMD","issuer_name":"TherapeuticsMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-087756-index.html","primary_entity_key":"0000025743","primary_entity_name":"TherapeuticsMD, Inc."},"word_count":171,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure.**\n\n \n\nOn August 11, 2026, TherapeuticsMD, Inc.,\na Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter ended June\n30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein\nby reference.\n\n \n\nThe information in this Item 7.01 and the information\ncontained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange\nAct of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933,\nas amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general\nincorporation language in the filing.\n\n \n\nThe Company does not have, and expressly disclaims,\nany obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances\non which any forward-looking statement is based."}